Leerink Partnrs Issues Optimistic Estimate for TENX Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Leerink Partnrs upped their Q2 2025 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a research note issued on Thursday, May 15th. Leerink Partnrs analyst D. Risinger now expects that the specialty pharmaceutical company will post earnings of ($1.07) per share for the quarter, up from their prior forecast of ($1.12). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q3 2025 earnings at ($3.37) EPS, Q4 2025 earnings at ($4.53) EPS, FY2026 earnings at ($6.07) EPS, FY2027 earnings at ($5.12) EPS, FY2028 earnings at ($3.32) EPS and FY2029 earnings at ($1.31) EPS.

A number of other brokerages have also recently issued reports on TENX. William Blair reissued an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a research report on Monday, March 10th. Guggenheim reaffirmed a “buy” rating and issued a $15.00 target price on shares of Tenax Therapeutics in a report on Thursday, May 15th. Finally, StockNews.com assumed coverage on shares of Tenax Therapeutics in a research note on Friday, May 16th. They set a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Tenax Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $17.50.

Tenax Therapeutics Stock Performance

Shares of TENX stock opened at $6.00 on Monday. The stock’s 50-day moving average is $5.85 and its two-hundred day moving average is $5.93. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $7.89. The firm has a market cap of $24.89 million, a price-to-earnings ratio of -2.42 and a beta of 1.92.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Wednesday, May 14th. The specialty pharmaceutical company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20.

Institutional Trading of Tenax Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Two Sigma Investments LP purchased a new stake in shares of Tenax Therapeutics during the fourth quarter worth approximately $84,000. Geode Capital Management LLC grew its position in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 5,964 shares during the last quarter. Millennium Management LLC acquired a new position in Tenax Therapeutics in the 4th quarter valued at $166,000. ADAR1 Capital Management LLC increased its stake in Tenax Therapeutics by 98.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock valued at $450,000 after buying an additional 34,048 shares during the period. Finally, Janus Henderson Group PLC purchased a new position in Tenax Therapeutics during the fourth quarter worth about $1,026,000. 1.67% of the stock is owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.